A new healthcare industry lawsuit is seeking to bring sweeping changes to the federal government’s controversial 340B drug discount program, aligning with broader efforts by the Trump administration to crack down on waste, fraud, and abuse in the U.S. healthcare system.
The legal challenge, filed by U.S. healthcare company Abbvie, centers on one of the most debated aspects of the 340B program: its vague and loosely enforced definition of who qualifies as a “patient.” Supporters of the lawsuit argue that tightening this definition could significantly curb abuses that have allowed hospitals to reap substantial financial windfalls while failing to pass savings on to actual human patients.
The 340B program, established to provide discounted medications to hospitals and health centers serving vulnerable populations, has come under increasing scrutiny in recent years. While the program was designed as a safety-net measure, critics say it has evolved into a system riddled with loopholes that large hospital systems exploit for profit, and often siphon funding and resources away from rural healthcare systems.
As outlined in the complaint and supporting commentary, hospitals have taken advantage of the program’s ambiguity in several ways. In some cases, institutions retroactively classify prescriptions as eligible for 340B discounts after they are filled, often without the patient or insurer ever knowing a discount applied, even though their identity was used to apply for the discount.
Additionally, critics point to the expansion strategies of major hospital systems, which have increasingly targeted patients with private insurance — allowing them to purchase discounted drugs and resell them at significantly higher prices. This practice, they argue, undermines the program’s original intent of supporting low-income and underserved populations.
The Trump administration has made reforming the 340B program a priority as part of its broader healthcare affordability agenda. As the Washington Reporter covered previously, officials introduced a pilot program designed to test a rebate-based model for distributing 340B discounts, with the goal of ensuring savings reach patients more directly. However, the initiative was quickly challenged in court by the American Hospital Association (AHA), highlighting the fierce resistance to basic transparency measures that might expose the underlying issues.
The newly filed lawsuit could prove to be a complementary effort, one that seeks to clarify the program’s rules rather than overhaul its structure outright. According to an executive involved in the case, the goal is to “establish this clear, sensible patient definition to get at what we see as the proliferation of abuse in the 340B program.”
Supporters of the lawsuit argue that such clarity is long overdue.
Joe Grogan, who served as a top healthcare advisor during the first Trump administration, welcomed the development, saying it is “good to see support building for President Trump’s effort to root out waste and abuse in the 340B gravy train.” He added that “more transparency and a real patient definition would be a strong place to start,” noting that years of inaction by both Congress and federal regulators allowed the program to “balloon and metastasize.”
Business leader Steve Forbes echoed those concerns, arguing that hospitals have used the program’s “vague structure” to divert taxpayer-subsidized benefits away from patients and toward unrelated priorities, including political activity. He described the lawsuit as a meaningful step toward restoring accountability and advancing the administration’s transparency goals.
Former Ohio Secretary of State Ken Blackwell also praised the effort, calling the fight against healthcare waste and abuse “one of the most important parts” of President Trump’s affordability agenda. Blackwell argued that hospitals have leveraged the program’s opacity to generate massive windfalls, funding everything from overseas ventures to luxury facilities, and even political initiatives. “This lawsuit will help deliver critical transparency in a broken system,” he added.
Advocates for reform say the issue ultimately comes down to restoring the program’s original mission.
Trent England emphasized that hospital systems have “betrayed patients by not passing on the benefits,” adding that meaningful reform begins with “a clear definition of a ‘patient.’”
Similarly, the Health Market and Policy Network noted that ambiguity in the current rules has made the program difficult to oversee and easy to exploit. “When the rules are vague, the program becomes harder to oversee and easier to stretch beyond its original safety-net purpose,” the group said, arguing that clearer standards would improve accountability and ensure discounts are tied to actual patient care.
At stake is not only the integrity of the program but also taxpayer dollars. Because 340B participants must operate as nonprofit entities, they receive significant tax advantages, effectively subsidizing their participation. Critics argue that without stronger guardrails, taxpayers are underwriting a system that too often fails to deliver meaningful benefits to patients.
For proponents, the case represents a critical opportunity to rein in a program they say has drifted far from its intended purpose, and to ensure that healthcare savings reach the patients who need them most.